Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | JAK2 | O60674 | 10/20 | 0.58 |
| ▸ | PAK4 | O96013 | 2/20 | 0.55 |
| ▸ | PLK4 | O00444 | 1/20 | 0.55 |
| ▸ | IGF1R | P08069 | 2/20 | 0.42 |
| ▸ | AURKA | O14965 | 2/20 | 0.41 |
| ▸ | ROCK2 | O75116 | 1/20 | 0.40 |
| ▸ | PAK1 | Q13153 | 2/20 | 0.40 |
| ▸ | RIPK1 | Q13546 | 1/20 | 0.40 |
| ▸ | NTRK1 | P04629 | 1/20 | 0.40 |
| ▸ | SRC | P12931 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1726771 | 0.85 | SPAST (0.47) | JAK2PAK4PLK4AURKAROCK2 | |
| SCHEMBL1722967 | 0.84 | JAK2 (0.42) | JAK2PAK4PLK4IGF1RROCK2 | |
| SCHEMBL3922274 | 0.80 | RET (0.41) | JAK2PAK4PLK4IGF1RAURKA | |
| SCHEMBL1268774 | 0.79 | PAK4 (0.48) | JAK2PAK4PLK4IGF1RAURKA | |
| SCHEMBL3926826 | 0.78 | RET (0.40) | JAK2PAK4PLK4IGF1RAURKA | |
| SCHEMBL3924185 | 0.78 | JAK2 (0.37) | JAK2PAK4PLK4AURKAPAK1 | |
| SCHEMBL4213948 | 0.78 | JAK2 (0.37) | JAK2PAK4PLK4AURKAPAK1 | |
| SCHEMBL3929547 | 0.77 | PAK1 (0.37) | JAK2PAK4PLK4IGF1RAURKA | |
| SCHEMBL916719 | 0.76 | POLB (0.36) | JAK2PAK4PLK4IGF1RROCK2 | |
| SCHEMBL2924820 | 0.75 | AURKA (0.54) | PAK4PLK4AURKASRC |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2344504-B1 | PYRROLOTRIAZINE KINASE INHIBITORS | BRISTOL MYERS SQUIBB CO (US) | 2014-06-04 | — | — | EP | disclosed |
| US-8445676-B2 | Pyrrolotriazine kinase inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2013-05-21 | — | — | US | disclosed |
| US-20110294816-A1 | PYRROLOTRIAZINE KINASE INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY | 2011-12-01 | — | — | US | disclosed |
| EP-2344504-A1 | PYRROLOTRIAZINE KINASE INHIBITORS | Bristol-Myers Squibb Company (US) | 2011-07-20 | — | — | EP | disclosed |
| WO-2010042684-A1 | PYRROLOTRIAZINE KINASE INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2010-04-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110294816-A1 | PYRROLOTRIAZINE KINASE INHIBITORS | JAK2, CSNK2A1, CSNK2A2 | JAK2 1/4885PAK4 733/4885PLK4 240/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.